FalconX Raises $210M Following 30x YoY Revenue Growth; Now Valued at $3.75 Billion
10.8.2021 18:00:00 EEST | Business Wire | Press release
FalconX, a digital assets and cryptocurrency financial services company that provides institutions trading, credit, and clearing across major cryptocurrencies, announced a $210M Series C financing round, valuing the company at $3.75 billion. The round was led by Altimeter Capital, Sapphire Ventures and existing investors B Capital Group and Tiger Global Management, with participation from Mirae Asset. Amex Ventures also increased its existing investment as part of this round. They join existing investors Accel, Accomplice VC, Coinbase Ventures, CMT Digital, Flybridge Capital Partners, Lightspeed Venture Partners, and Avon Ventures, a venture capital fund affiliated with FMR LLC, the parent company of Fidelity Investments.
In just three years, FalconX has become one of the most highly valued institutional cryptocurrency companies in the world, driven by strong unit economics, profitability, and revenue growth across business lines. FalconX leverages machine learning to provide institutions a single counterparty with access to global cryptocurrency liquidity with 99.9%+ uptime through its web interface, APIs, and 24/7/365 white glove trading desk. Its credit business enables institutions to access short term financing for trades – filling the gap between long term loans and derivatives markets for institutions looking to increase their balance sheet efficiency in an elastic manner. FalconX plans to officially announce several new product offerings in the coming months, each of which are currently live, growing quickly, and profitable.
“FalconX is the trusted one-stop-shop for the world’s leading institutional cryptocurrency market participants – providing the technology, security, and reliability necessary to power their strategies at scale,” said Raghu Yarlagadda, CEO and Co-Founder of FalconX. “Serving the world’s leading investors, we are at the forefront of a megatrend which will fundamentally change financial services – if you wouldn’t accept Google or Amazon only working 5 days a week – why aren’t financial services 24/7, truly global, and more accessible? Blockchain has proven that it is possible at scale, and FalconX is excited to lead that change.”
FalconX’s growth is driven by demand from a diverse range of institutional market participants, including some of the world’s largest financial institutions, hedge funds, asset managers, venture capital firms, payment providers and investment applications – for secure, reliable, and bespoke cryptocurrency products. FalconX will use the funding from the Series C round to expand its product lines, explore strategic acquisitions, and continue to hire great talent globally, including key executives with backgrounds at the convergence of traditional financial markets, digital assets and technology.
Quotes on the Round :
“FalconX has clearly positioned itself as a leading institutional cryptocurrency company – we’re excited to back a market leader in an industry in the early innings of strong secular growth. FalconX’s product velocity and pace of innovation is remarkable and we believe will play an important role in the future of financial and crypto market infrastructure.” - Brad Gerstner, Founder & CEO, Altimeter Capital
“FalconX is recognized as a best-in-class institutional platform for cryptocurrency that facilitates billions in crypto trading each month. We have repeatedly heard institutional customers praise FalconX for their unmatched reliability and a one-stop-shop infrastructure platform to meet all their long-term crypto trading needs. We’re excited to partner with the FalconX team to build the de-facto platform that powers global discovery, exchange and transfer of all digital assets worldwide.” - Rashmi Gopinath, General Partner, B Capital Group
“FalconX has delivered strong business growth while building a world-class team that brings together talent from Silicon Valley, traditional financial markets and the blockchain ecosystem. This team is uniquely positioned to partner with its customers to create winning strategies and deliver new products that help them find scale.” - Rajeev Dham, Partner, Sapphire Ventures
“As institutional investors continue entering the cryptocurrency market, FalconX has significantly scaled its business and product lines to meet their needs. We’re excited to double down on the leading one-stop-shop for institutional trading, credit and clearing.” - Scott Shleifer, Partner, Tiger Global Management
About FalconX
FalconX is an all-in-one cryptocurrency and digital assets financial services platform facilitating trading, credit, and clearing for institutions. The company is backed by Accel, Accomplice VC, Altimeter Capital, B Capital Group, American Express Ventures, CMT Digital, Coinbase Ventures, Flybridge Capital Partners, Lightspeed Venture Partners, Mirae Asset, Sapphire Ventures, Tiger Global Management and Avon Ventures, a venture capital fund affiliated with FMR LLC, the parent company of Fidelity Investments. FalconX has offices in Silicon Valley, Chicago, Bengaluru, and Malta. For more information visit falconx.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005701/en/
Contact information
FalconX
Kelsey Williams
falconx@strangebrewstrategies.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
